The NSCLC subtype adenocarcinoma has been the most advanced cancer subtype in the implementation of targeted therapies, and at the current date, two categories of MET tyrosine kinase inhibitors (TKI) have been validated (Table 2), such as type I, which included crizotinib, capmatinib, tepotinib, and savolitinib that binds to an active MET conformation, and type II (cabozantinib, merestinib, and glesatinib) that binds to an inactive MET [33]. This evidence concerns the gene MET and cancer.